GBI, Hyprocell collaborate to offer cell line development

By Nick Taylor

- Last updated on GMT

CMO Goodwin Biotechnology Inc (GBI) is collaborating with Hyprocell to help clients that need manufacturing services but have a sub-optimal cell line producing low concentrations.

Joining with Hyprocell is intended to help GBI become a “one stop shop​” capable of supporting clients’ cDNA synthesis, transfection and clone selection needs, as well as process development and manufacturing.

"Most of our customers are looking for one-stop shop type of CMO (contract manufacturer organisation)services and Hyprocell is a perfect partner to collaborate with to satisfy the market need​", said Bansi Bhan, interim CEO at GBI.

In the past GBI would refer clients needing cell line development services to contract research organisations (CRO), including Hyprocell, but there are benefits to formalising the relationship, Muctarr Sesay, vice president of process development at GBI told Outsourcing-Pharma.

Sesay believes that having a communicative and transparent relationship with Hyprocell will facilitate a smooth transition from cell line creation to GMP production. In turn, this will help shorten the time it takes some clients to reach clinical trials.

Hyprocell uses “cutting edge technology​” while retaining “small company innovation and flexibility​”, according to Bhan. Sesay added that clients in a suitable financial and developmental situation will also have the option of parallel working.

The service providers will also benefit from the arrangement. GBI will become the preferred CMO for Hyprocell clients that want production services. In addition Hyprocell will receive business from clients of GBI needing cell line services.

GBI and Hyprocell have been collaborating “for a while​”, added Sesay, but the economic situation has restricted uptake so far. Despite the wider economic challenges GBI and Hyprocell “are working towards projects​”, Sesay said.

Related news

Related products

show more

Reliability, scale, and security of supply

Reliability, scale, and security of supply

Content provided by Univar Solutions USA | 28-Aug-2024 | Product Brochure

Univar Solutions Pharmaceutical Ingredients is proud to offer one of the most expansive portfolios of 15,000+ products, including high-purity solvents,...

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us

Products

View more

Webinars